In this regard, it is worth mentioning that in the context of breast cancer, the use of TRIM25 targeting DNA-based “chimeric siRNA”, in which sequence fragments are substituted with DNA, is supposed to have fewer off-target effects and less immunogenic potential and efficiently suppressed proliferation and cell cycle progression of MCF-7 cells as well as in vivo growth of MCF-7-derived tumors in nude mice [58]. The gene discussed is TRIM25; the disease is breast cancer.